Press release
Hepatic Tumor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Hepatic Tumor Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatic Tumor Pipeline Outlook [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hepatic Tumor Pipeline Report
* On 22 August 2025, Massachusetts General Hospital announced a study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer. A phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the intervention is being studied.
* On 12 August 2025, Eureka Therapeutics Inc . conducted a study is to evaluate an investigational ARTEMIS Registered ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC). In this study, a patient's T cells are collected and genetically modified to express Eureka's proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells.
* DelveInsight's Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
* The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
* Promising Hepatic Tumor Pipeline Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, NIK-333(peretinoin), Sorafenib, SonoVue Registered , Talaporfin sodium, NV1020, Pemetrexed , and others.
Stay ahead with the most recent pipeline outlook for Hepatic Tumor. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hepatic Tumor Treatment Drugs [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatic Tumor Emerging Drugs Profile
* Namodenoson: Can Fite Biopharma
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.
* MTL CEBPA: MiNA Therapeutics
MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.
* Amivantamab: Janssen Research & Development, LLC
Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.
* Fostroxacitabine bralpamide: Medivir AB
Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.
* ETN101: Etnova Therapeutics Corp.
ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.
The Hepatic Tumor Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hepatic Tumor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatic Tumor Treatment.
* Hepatic Tumor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hepatic Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatic Tumor market
Explore groundbreaking therapies and clinical trials in the Hepatic Tumor Pipeline. Access DelveInsight's detailed report now! @ New Hepatic Tumor Drugs [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatic Tumor Companies
Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
Hepatic Tumor Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical.
Hepatic Tumor Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Hepatic Tumor Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatic Tumor Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hepatic Tumor Pipeline Report
* Coverage- Global
* Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
* Hepatic Tumor Pipeline Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, NIK-333(peretinoin), Sorafenib, SonoVue Registered , Talaporfin sodium, NV1020, Pemetrexed , and others.
* Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hepatic Tumor Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatic Tumor Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hepatic Tumor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Namodenoson: Can Fite Biopharma
* Mid Stage Products (Phase II)
* MTL CEBPA : MiNA Therapeutics
* Early Stage Products (Phase I)
* Comparative Analysis
* ETN101: Etnova Therapeutics Corp.
* Inactive Products
* Hepatic Tumor Key Companies
* Hepatic Tumor Key Products
* Hepatic Tumor - Unmet Needs
* Hepatic Tumor - Market Drivers and Barriers
* Hepatic Tumor - Future Perspectives and Conclusion
* Hepatic Tumor Analyst Views
* Hepatic Tumor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatic-tumor-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatic-tumor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatic Tumor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4158917 • Views: …
More Releases from ABNewswire
SERM Market Outlook 2034: Clinical Trials, FDA Approvals, Market Size, Therapies …
The Selective Estrogen Receptor Modulators (SERMs) market is anticipated to witness significant expansion in the coming years, fueled by the increasing prevalence of cancer, heightened awareness of SERM therapies, and a growing pipeline of candidates in clinical trials and regulatory review across multiple companies.
SERMs Market Summary
The Selective Estrogen Receptor Modulators (SERMs) market is expected to witness significant growth in the coming years, fueled by the increasing incidence of cancer, rising…
Advanced Ovarian Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA …
DelveInsight's, "Advanced Ovarian Cancer Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's…
Acute Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Glaucoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals …
DelveInsight's, "Glaucoma Pipeline Insight, 2025," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glaucoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Glaucoma…
More Releases for Hepatic
Top Trends Transforming the Hepatic Encephalopathy Market Landscape in 2025: Inn …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Will the Hepatic Encephalopathy Industry Market Size Be by 2025?
The market size for hepatic encephalopathy has witnessed significant expansion in the past few years. The market, projected to rise from $1.72 billion in 2024 to $1.8 billion in 2025, is estimated to have a compound annual growth…
Liver Disease Treatment Market: Advancing Hepatic Care
The liver disease treatment market encompasses a range of medications, therapies, and procedures aimed at managing and curing liver conditions such as hepatitis, fatty liver disease, cirrhosis, liver cancer, and liver failure. Given the liver's critical role in metabolic processes, detoxification, and protein synthesis, effective treatment options are essential for maintaining overall health. The market is influenced by factors such as the rising prevalence of liver diseases, advancements in medical…
Hepatic Encephalopathy Treatment Market - Transforming hepatic encephalopathy ca …
Newark, New Castle, USA: The "Hepatic Encephalopathy Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hepatic Encephalopathy Treatment Market: https://www.growthplusreports.com/report/hepatic-encephalopathy-treatment-market/8818
This latest report researches the industry structure,…
Hepatic Encephalopathy Treatment Market - Driving Progress, Inspiring Hope: Lead …
Newark, New Castle, USA - new report, titled Hepatic Encephalopathy Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Hepatic Encephalopathy Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Hepatic Encephalopathy Treatment market. The report offers an overview of…
Hepatic Biomarkers Market Size & Analysis - Forecast to 2026
The findings reviewed by GME stated that the Global Hepatic Biomarkers Market will grow at a CAGR value of 6.5% from 2021 to 2026. The increasing prevalence of chronic diseases, like cancers and other chronic diseases, is raising the use of hepatic biomarkers all over the world.
Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Global Hepatic Biomarkers Market - Forecast to 2026"…
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017
"The Report Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.
Liver failure is severe deterioration of liver function. Liver failure occurs when…
